View of STRUCTURE-BASED VIRTUAL SCREENING STUDY OF FDA‑APPROVED DRUGS TO INHIBIT TP53 72 ARG/PRO VARIANT IDENTIFIED IN ACUTE LYMPHOCYTIC PATIENT VIA WHOLE EXOME SEQUENCING

Return to Article Details STRUCTURE-BASED VIRTUAL SCREENING STUDY OF FDA‑APPROVED DRUGS TO INHIBIT TP53 72 ARG/PRO VARIANT IDENTIFIED IN ACUTE LYMPHOCYTIC PATIENT VIA WHOLE EXOME SEQUENCING Download Download PDF